The Zhitong Finance App learned that Pfizer (PFE.US) announced on Wednesday that it has reached an agreement with Blackstone (BX.US) to receive up to 1.5 billion US dollars in funding to support the development of its experimental monthly obesity treatment. According to statements issued by the two companies, the funds managed by Blackstone Life Sciences under Blackstone will cover up to $1.5 billion in development costs for the drug by 2028. The drug is an injectable berobenatide, and Pfizer is testing it as a monthly weight loss injection.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.